Sukumar Nagendran
CIK: 0001665124
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (20 total)
- Jul 10, 2026TSHA
Taysha Gene Therapies, Inc.
Sale(S)Direct200K shares at avg. $6.24$1.2M - Jun 10, 2026SLDB
Solid Biosciences Inc.
Award(A)DirectDirector Stock Option (Right to Buy)
77.5K shares- - Apr 10, 2026TSHA
Taysha Gene Therapies, Inc.
Exercise(M)Direct19K shares at avg. $1.71$33K - Apr 10, 2026TSHA
Taysha Gene Therapies, Inc.
Sale(S)Direct200K shares at avg. $4.46$892K - Jan 26, 2026TSHA
Taysha Gene Therapies, Inc.
Sale(S)Direct26.9K shares at avg. $4.61$124K - Jan 23, 2026TSHA
Taysha Gene Therapies, Inc.
Sale(S)Direct89.1K shares at avg. $4.75$423K - Jan 12, 2026TSHA
Taysha Gene Therapies, Inc.
Exercise(M)Direct111.3K shares at avg. $0.70$78K - Jan 12, 2026TSHA
Taysha Gene Therapies, Inc.
Award(A)Direct427K shares- - Jan 12, 2026TSHA
Taysha Gene Therapies, Inc.
Sale(S)Direct200K shares at avg. $4.71$942K - Jan 12, 2026TSHA
Taysha Gene Therapies, Inc.
Exercise(M)Direct88.7K shares at avg. $1.71$152K - Dec 1, 2025TSHA
Taysha Gene Therapies, Inc.
Exercise(M)Direct260K shares at avg. $1.71$445K - Dec 1, 2025TSHA
Taysha Gene Therapies, Inc.
Sale(S)Direct260K shares at avg. $4.51$1.2M - Nov 28, 2025TSHA
Taysha Gene Therapies, Inc.
Sale(S)Direct110.1K shares at avg. $4.75$523K - Nov 28, 2025TSHA
Taysha Gene Therapies, Inc.
Exercise(M)Direct40K shares at avg. $1.71$68K - Nov 28, 2025TSHA
Taysha Gene Therapies, Inc.
Exercise(M)Direct70.2K shares at avg. $0.70$49K - Sep 10, 2025TSHA
Taysha Gene Therapies, Inc.
Sale(S)Direct200K shares at avg. $3.23$646K - Sep 10, 2025TSHA
Taysha Gene Therapies, Inc.
Exercise(M)Direct41.2K shares at avg. $0.70$29K - Aug 21, 2025TSHA
Taysha Gene Therapies, Inc.
Sale(S)Direct57.1K shares at avg. $2.85$163K - Jun 12, 2025SLDB
Solid Biosciences Inc.
Award(A)DirectDirector Stock Option (Right to Buy)
77.5K shares- - Jan 2, 2025TSHA
Taysha Gene Therapies, Inc.
Award(A)Direct324.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 10, 2026 |  TSHA Taysha Gene Therapies, Inc. | Sale(S) | 200,000 | $6.24 | $1,248,000 | Direct |
| Jun 10, 2026 |  SLDB Solid Biosciences Inc. | Award(A) Director Stock Option (Right to Buy) | 77,500 | - | - | Direct |
| Apr 10, 2026 | TSHA Taysha Gene Therapies, Inc. | Exercise(M) | 19,021 | $1.71 | $32,526 | Direct |
| Apr 10, 2026 | TSHA Taysha Gene Therapies, Inc. | Sale(S) | 200,000 | $4.46 | $892,000 | Direct |
| Jan 26, 2026 | TSHA Taysha Gene Therapies, Inc. | Sale(S) | 26,918 | $4.61 | $124,092 | Direct |
| Jan 23, 2026 | TSHA Taysha Gene Therapies, Inc. | Sale(S) | 89,132 | $4.75 | $423,377 | Direct |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | Exercise(M) | 111,324 | $0.70 | $77,804 | Direct |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | Award(A) | 427,000 | - | $0 | Direct |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | Sale(S) | 200,000 | $4.71 | $942,000 | Direct |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | Exercise(M) | 88,676 | $1.71 | $151,636 | Direct |
| Dec 1, 2025 | TSHA Taysha Gene Therapies, Inc. | Exercise(M) | 260,047 | $1.71 | $444,680 | Direct |
| Dec 1, 2025 | TSHA Taysha Gene Therapies, Inc. | Sale(S) | 260,047 | $4.51 | $1,172,812 | Direct |
| Nov 28, 2025 | TSHA Taysha Gene Therapies, Inc. | Sale(S) | 110,125 | $4.75 | $523,094 | Direct |
| Nov 28, 2025 | TSHA Taysha Gene Therapies, Inc. | Exercise(M) | 39,953 | $1.71 | $68,320 | Direct |
| Nov 28, 2025 | TSHA Taysha Gene Therapies, Inc. | Exercise(M) | 70,172 | $0.70 | $49,043 | Direct |
| Sep 10, 2025 | TSHA Taysha Gene Therapies, Inc. | Sale(S) | 200,000 | $3.23 | $646,000 | Direct |
| Sep 10, 2025 | TSHA Taysha Gene Therapies, Inc. | Exercise(M) | 41,150 | $0.70 | $28,760 | Direct |
| Aug 21, 2025 | TSHA Taysha Gene Therapies, Inc. | Sale(S) | 57,054 | $2.85 | $162,604 | Direct |
| Jun 12, 2025 | SLDB Solid Biosciences Inc. | Award(A) Director Stock Option (Right to Buy) | 77,500 | - | - | Direct |
| Jan 2, 2025 | TSHA Taysha Gene Therapies, Inc. | Award(A) | 324,500 | - | $0 | Direct |
1-20 of 20 transactions
About Nagendran Sukumar
Nagendran Sukumar (SEC CIK 0001665124) files insider reports with the SEC as President and Head of R&D of Taysha Gene Therapies, Inc. (TSHA) and Director of Solid Biosciences Inc. (SLDB).
Signal8 holds 10 ownership filings by Nagendran Sukumar, all Form 4s, filed between Jan 3, 2025 and Jul 10, 2026. Those filings report 20 transactions, from Jan 2, 2025 to Jul 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Nagendran Sukumar's filings is in DALLAS, TX.
Recent filings by Nagendran Sukumar
- Jul 10, 2026: Open-market sale of TSHA shares (Form 4, code S).
- Jun 10, 2026: Grant or award of SLDB derivative securities (Form 4, code A).
- Apr 10, 2026: Option exercise of TSHA shares (Form 4, code M).
- Apr 10, 2026: Open-market sale of TSHA shares (Form 4, code S).
- Jan 26, 2026: Open-market sale of TSHA shares (Form 4, code S).
Other insiders filing for Taysha Gene Therapies, Inc. (TSHA)
- Stalfort John A III, Director
- Donenberg Phillip B., Director
- Long Alison S, Director
- Sepp-Lorenzino Laura, Director
- Alam Kamran, CHIEF FINANCIAL OFFICER
- Nolan Sean P., Chief Executive Officer